Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (TEVA) | December 28, 2016

Guggenheim reissued their buy rating on shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in a report released on Friday. The firm currently has a $80.00 target price on the stock…...

Teva Pharmaceutical Industries Ltd. (TEVA) | December 28, 2016

Snow Capital Management LP reduced its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 10.2% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 965,986 shares of the company’s stock after selling 110,053 shares during the period…...

Pharmaceutical | December 06, 2016

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by inves...

Pharamaceutical | January 05, 2017

Klingenstein Fields & Co Llc decreased its stake in Teva Pharmaceutical Industries (TEVA) by 45.58% based on its latest 2016Q3 regulatory filing with the SEC. Klingenstein Fields & Co Llc sold 87,893 shares as the company’s stock declined 8.07% while stock markets rallied. The institutional investor held 104,954 shares of the major pharmaceuticals company at the end of 2016Q3, valued at $4.83M, down from 192,847 at the end of the previous reported quarter. Klingenstein Fields & Co Llc who had be...